Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Stock Has Consensus Target Price of $18.25

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) has earned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $18.25.

A number of research analysts have recently issued reports on UNCY shares. Zacks Research upgraded Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 19th. B. Riley Financial restated a “buy” rating and set a $20.00 price objective (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Wall Street Zen raised Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Benchmark reiterated a “speculative buy” rating and issued a $15.00 target price (up from $13.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 20th. Finally, Guggenheim reiterated a “buy” rating and issued a $25.00 target price (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday, August 13th.

Unicycive Therapeutics Stock Performance

NASDAQ UNCY opened at $4.22 on Friday. The company has a market capitalization of $117.53 million, a price-to-earnings ratio of -2.41 and a beta of 1.83. The company’s 50-day simple moving average is $5.09 and its two-hundred day simple moving average is $6.25. Unicycive Therapeutics has a one year low of $3.93 and a one year high of $8.74.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.41. Equities analysts expect that Unicycive Therapeutics will post -1.16 earnings per share for the current fiscal year.

Key Unicycive Therapeutics News

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Analysts remain constructive: Unicycive has an average “Moderate Buy” rating, while HC Wainwright reiterated a Buy rating and a $13 price target. The firm improved several longer-term EPS forecasts, including estimates for fiscal 2027 through 2030, suggesting expectations for commercialization and eventual profitability remain intact. Unicycive analyst rating HC Wainwright earnings estimates
• Positive Sentiment: Board addition: Unicycive appointed Meredith Manning, M.B.A., to its board. The addition may strengthen the company’s governance and business expertise as it advances its kidney-disease therapies, although the announcement did not include a new clinical or regulatory milestone. Unicycive appoints Meredith Manning
• Neutral Sentiment: Mixed earnings outlook: HC Wainwright raised its full-year 2026 EPS estimate modestly, but still expects a loss of $1.38 per share. It lowered its 2027 first-quarter estimate while raising estimates for later quarters and projects a return to positive EPS in the fourth quarter of 2027. Separately, a report said HC Wainwright cut its price target, creating a mixed near-term signal. HC Wainwright price target report
• Negative Sentiment: Class-action litigation is the main headwind: Multiple law firms are soliciting investors for a lead-plaintiff role by November 2, 2026, in a lawsuit covering purchases from December 29, 2025, through June 29, 2026. The allegations include reliance on a contract manufacturer with prior FDA current good manufacturing practice deficiencies, which allegedly contributed to a second Complete Response Letter and a reported 39.1% one-day stock collapse. The litigation raises potential financial, regulatory and reputational risks and is likely weighing on UNCY. Unicycive shareholder lawsuit allegations Kaplan Fox class action notice

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of UNCY. Seven Fleet Capital Management LP raised its stake in shares of Unicycive Therapeutics by 85.6% during the 2nd quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock worth $521,000 after acquiring an additional 47,700 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Unicycive Therapeutics in the second quarter valued at approximately $248,000. Bank of America Corp DE boosted its stake in Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after acquiring an additional 29,378 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Unicycive Therapeutics in the first quarter valued at approximately $161,000. Finally, Dimensional Fund Advisors LP purchased a new position in Unicycive Therapeutics in the first quarter worth $940,000. Hedge funds and other institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for patients with kidney disease. The company’s lead product candidate is oxylanthanum carbonate, an oral phosphate binder being developed to treat hyperphosphatemia, or elevated phosphate levels, in patients with chronic kidney disease, including those receiving dialysis.

Oxylanthanum carbonate is designed to bind dietary phosphate in the gastrointestinal tract, helping reduce the amount of phosphate absorbed into the bloodstream.